Health & Fitness
Health and FitnessHealth and Fitness 
Wed, December 8, 2010
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - WOPRAI
[ Wed, Dec 08th 2010
] - WOPRAI
[ Wed, Dec 08th 2010
] - WOPRAI
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
[ Wed, Dec 08th 2010
] - Market Wire
Tue, December 7, 2010
[ Tue, Dec 07th 2010
] - Market Wire
[ Tue, Dec 07th 2010
] - Market Wire
[ Tue, Dec 07th 2010
] - Market Wire
[ Tue, Dec 07th 2010
] - Market Wire
[ Tue, Dec 07th 2010
] - Market Wire
[ Tue, Dec 07th 2010
] - WOPRAI
[ Tue, Dec 07th 2010
] - WOPRAI
[ Tue, Dec 07th 2010
] - WOPRAI
[ Tue, Dec 07th 2010
] - WOPRAI
[ Tue, Dec 07th 2010
] - WOPRAI
[ Tue, Dec 07th 2010
] - WOPRAI
[ Tue, Dec 07th 2010
] - Market Wire
[ Tue, Dec 07th 2010
] - Market Wire
[ Tue, Dec 07th 2010
] - Market Wire
[ Tue, Dec 07th 2010
] - Market Wire
[ Tue, Dec 07th 2010
] - Market Wire
[ Tue, Dec 07th 2010
] - Market Wire
[ Tue, Dec 07th 2010
] - Market Wire
[ Tue, Dec 07th 2010
] - Market Wire
[ Tue, Dec 07th 2010
] - Market Wire
[ Tue, Dec 07th 2010
] - Market Wire
[ Tue, Dec 07th 2010
] - Market Wire
[ Tue, Dec 07th 2010
] - Market Wire
[ Tue, Dec 07th 2010
] - Market Wire
[ Tue, Dec 07th 2010
] - Market Wire
[ Tue, Dec 07th 2010
] - Market Wire
[ Tue, Dec 07th 2010
] - Market Wire
[ Tue, Dec 07th 2010
] - Market Wire
[ Tue, Dec 07th 2010
] - Market Wire
[ Tue, Dec 07th 2010
] - Market Wire
[ Tue, Dec 07th 2010
] - Market Wire
[ Tue, Dec 07th 2010
] - Market Wire
[ Tue, Dec 07th 2010
] - Market Wire
[ Tue, Dec 07th 2010
] - Market Wire
[ Tue, Dec 07th 2010
] - Market Wire
[ Tue, Dec 07th 2010
] - Market Wire
[ Tue, Dec 07th 2010
] - Market Wire
[ Tue, Dec 07th 2010
] - Market Wire
[ Tue, Dec 07th 2010
] - Market Wire
[ Tue, Dec 07th 2010
] - Market Wire
[ Tue, Dec 07th 2010
] - Market Wire
[ Tue, Dec 07th 2010
] - Market Wire
Retrospectieve analyse van klinische gegevens uit fase-III onderzoek naar REVLIMID (MDS-004) laat belangrijke verbetering zien
BOUDRY, Switzerland--([ BUSINESS WIRE ])--Celgene International Srl (NASDAQ: CELG) maakt vandaag de nieuwe resultaten bekend uit een retrospectieve analyse van een willekeurig, internationaal fase-III onderzoek naar REVLIMID (lenalidomide) voor de behandeling van patinten met myelodysplastisch syndroom (MDS) met een chromosomale afwijking van 5q deletie. Deze resultaten zijn gepresenteerd tijdens de 52ste jaarlijkse bijeenkomst van de American Society of Hematology, gehouden in Orlando, Florida. De conclusie luidde dat voor patinten die met lenalidomide werden behandeld het cumulatieve driejarige risico van progressie naar acute myelode leukemie (AML) op 25,1 procent lag en de overleving op 56,0 procent.
Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal welke als enige juridische geldigheid beoogt.